Back to News
Market Impact: 0.25
BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst EstimatesCompany Fundamentals
BridgeBio Pharma reported a quarterly loss of $0.42 per share, narrower than the Zacks Consensus Estimate loss of $0.60 and the year-ago loss of $0.95 per share. The reported loss was $0.18 per share better than consensus.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BBIO0.55
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates